{"disease":{"id":"cns-lymphoma","name":"cns lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00840047","title":"Methionine PET/CT Studies In Patients With Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":503,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT05108298","title":"Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Eastern Cooperative Oncology Group","has_results":false},{"nct_id":"NCT05518383","title":"B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT04947319","title":"Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":119,"lead_sponsor_name":"Ono Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07350850","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT02315326","title":"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06439420","title":"CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Virginia Commonwealth University","has_results":false},{"nct_id":"NCT05735717","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT05036564","title":"Diagnosis; Objective RespOnse; THErApy","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT04438044","title":"A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":61,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT05293990","title":"Usefulness of Gadovist-enhanced FLAIR Imaging","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Ryoo, In Seon","has_results":false},{"nct_id":"NCT06755619","title":"CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Nordic Lymphoma Group","has_results":false},{"nct_id":"NCT07410520","title":"PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07523737","title":"Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT06946407","title":"Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"FengYan Jin","has_results":false},{"nct_id":"NCT04006561","title":"Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost","phase":"","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT05351593","title":"Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"James Rubenstein","has_results":false},{"nct_id":"NCT06737250","title":"NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"NOBO Medicine","has_results":false},{"nct_id":"NCT04514393","title":"Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":33,"lead_sponsor_name":"Huiqiang Huang","has_results":false},{"nct_id":"NCT06876688","title":"Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06646211","title":"High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04627753","title":"Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Kim, Seok Jin","has_results":false},{"nct_id":"NCT05926427","title":"Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT03703167","title":"Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04656431","title":"Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"James Rubenstein","has_results":false},{"nct_id":"NCT06343311","title":"T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Estrella Biopharma, Inc.","has_results":false},{"nct_id":"NCT06730542","title":"Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Juan P. Alderuccio, MD","has_results":false},{"nct_id":"NCT07188077","title":"Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Ting YANG","has_results":false},{"nct_id":"NCT05274139","title":"Treatment of Primary CNS Lymphoma ( FTD )","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Mingzhi Zhang","has_results":false},{"nct_id":"NCT06322342","title":"Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Reveal Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT04841434","title":"A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT06132737","title":"[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Pentixapharm AG","has_results":false},{"nct_id":"NCT01542918","title":"Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"James Rubenstein","has_results":false},{"nct_id":"NCT05211336","title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":14,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04134117","title":"Tisagenlecleucel In Primary CNS Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Matthew J. Frigault, M.D.","has_results":false},{"nct_id":"NCT05242146","title":"GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.","has_results":false},{"nct_id":"NCT07062627","title":"Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Hyungwoo Cho","has_results":false},{"nct_id":"NCT01251913","title":"A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes","phase":"","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04073147","title":"Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Klinikum Stuttgart","has_results":false},{"nct_id":"NCT05222269","title":"[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Pentixapharm AG","has_results":false}],"total":41},"guidelines":[],"source":"Drug Landscape verified database"}